Publication:
Molecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models.

dc.contributor.authorBenedicto, Ignacio
dc.contributor.authorDorado, Beatriz
dc.contributor.authorAndres, Vicente
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderUnión Europea. Comisión Europea. H2020es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)es_ES
dc.contributor.funderProgeria Research Foundationes_ES
dc.contributor.funderFundación La Marató TV3es_ES
dc.contributor.funderComunidad de Madrid (España)es_ES
dc.contributor.funderFundación ProCNICes_ES
dc.date.accessioned2022-11-21T09:51:10Z
dc.date.available2022-11-21T09:51:10Z
dc.date.issued2021
dc.description.abstractHutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disease that recapitulates many symptoms of physiological aging and precipitates death. Patients develop severe vascular alterations, mainly massive vascular smooth muscle cell loss, vessel stiffening, calcification, fibrosis, and generalized atherosclerosis, as well as electrical, structural, and functional anomalies in the heart. As a result, most HGPS patients die of myocardial infarction, heart failure, or stroke typically during the first or second decade of life. No cure exists for HGPS, and therefore it is of the utmost importance to define the mechanisms that control disease progression in order to develop new treatments to improve the life quality of patients and extend their lifespan. Since the discovery of the HGPS-causing mutation, several animal models have been generated to study multiple aspects of the syndrome and to analyze the contribution of different cell types to the acquisition of the HGPS-associated cardiovascular phenotype. This review discusses current knowledge about cardiovascular features in HGPS patients and animal models and the molecular and cellular mechanisms through which progerin causes cardiovascular disease.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis study was supported by grants to V.A. from the Spanish Ministerio de Ciencia e Innovación (MCIN) (PID2019-108489RB-I00) and the Instituto de Salud Carlos III (ISCIII) (grant AC17/00067, as coordinator of the E-Rare Joint Transnational call 2017 project “TREAT-HGPS,” European Union Horizon 2020 Framework Programme) with co-funding from the European Regional Development Fund (ERDF, “A way to build Europe”), the Progeria Research Foundation (Award PRF 2019–77), and the Fundación Marató TV3 (38/C/2020). I.B. was supported by the Comunidad Autónoma de Madrid (grant 2017-T1/BMD-5247). The CNIC is supported by the MCIN, the ISCIII, and the Pro CNIC Foundation.es_ES
dc.format.number5es_ES
dc.format.volume10es_ES
dc.identifier.citationCells. 2021 May 11;10(5):1157.es_ES
dc.identifier.doi10.3390/cells10051157es_ES
dc.identifier.e-issn2073-4409es_ES
dc.identifier.journalCellses_ES
dc.identifier.pubmedID34064612es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15201
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-108489RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/AC17/00067es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/38/C/2020es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/2017-T1/BMD-5247es_ES
dc.relation.publisherversion10.3390/cells10051157es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Fisiopatología Cardiovascular Molecular y Genéticaes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshDisease Models, Animales_ES
dc.subject.meshAginges_ES
dc.subject.meshAnimalses_ES
dc.subject.meshAtherosclerosises_ES
dc.subject.meshCardiovascular Diseaseses_ES
dc.subject.meshCardiovascular Systemes_ES
dc.subject.meshClinical Trials as Topices_ES
dc.subject.meshCytoskeletones_ES
dc.subject.meshEndothelium, Vasculares_ES
dc.subject.meshFibrosises_ES
dc.subject.meshHeart Diseaseses_ES
dc.subject.meshHumanses_ES
dc.subject.meshLamin Type Aes_ES
dc.subject.meshMicees_ES
dc.subject.meshMuscle, Smoothes_ES
dc.subject.meshMuscle, Smooth, Vasculares_ES
dc.subject.meshMyocardial Infarctiones_ES
dc.subject.meshPhenotypees_ES
dc.subject.meshProgeriaes_ES
dc.subject.meshStrokees_ES
dc.subject.meshVascular Calcificationes_ES
dc.titleMolecular and Cellular Mechanisms Driving Cardiovascular Disease in Hutchinson-Gilford Progeria Syndrome: Lessons Learned from Animal Models.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication2c0f32cd-37df-4f84-8525-e7b6dd84d087
relation.isAuthorOfPublication6355de6c-f1f5-451f-a89f-9bcc764f6852
relation.isAuthorOfPublication3bb85851-071a-490a-976b-c234983847a7
relation.isAuthorOfPublication.latestForDiscovery2c0f32cd-37df-4f84-8525-e7b6dd84d087

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Cells 2021 May 11 10 Molecular and Cellular Mechanisms Driving.pdf
Size:
980.3 KB
Format:
Adobe Portable Document Format
Description:
Artículo